P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY. (23rd June 2022)

• Record Type: Journal Article
• Authors: Tivey, A.; Shotton, R.; Eyre, T. A.; Lewis, D.; Crosbie, N.; Nga, E.; Guerrero Camacho, R.; Swe, W.; Marr, H.; Rees, C.; Moule, S.; Sutton, T.; Wrench, D.; Thomas, N.; Wilson, M.; Bailey, J.; Prahladan, M.; Hodson, A.; Koppana, M.; Smith, S.; Jones, S.; Miall, F.; Norman, J.; Davies, E.; Hildyard, C.; Lowry, L.; Paneesha, S.; Qureshi, I.; Beech, A.; Bedford, C.; Everden, A.; Tucker, D.; Wright, J.; Goddard, J.; Nicholson, T.; Wilson, J.; Lord, A.; Jackson, B.; Flont, M.; Gibb, A.; Linton, K.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 1031
• Page End: 1032
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000847432.95668.eb
• Languages: English
• ISSNs: 2572-9241